Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenues:        
Total revenues $ 41,848 $ 24,808 $ 116,429 $ 93,279
Operating costs and expenses:        
Cost of Captisol 6,353 3,147 18,680 9,410
Amortization of intangibles 3,875 3,552 11,285 10,560
Research and development 12,853 13,742 37,476 37,244
General and administrative 15,020 9,525 34,353 31,607
Total operating costs and expenses 38,101 29,966 101,794 88,821
Gain from sale of Promacta license 0 0 0 812,797
Income (loss) from operations 3,747 (5,158) 14,635 817,255
Other income (expense):        
Loss from short-term investments (9,862) (13,297) (17,143) (8,524)
Interest income 991 7,396 7,690 22,590
Interest expense (6,269) (8,993) (21,030) (26,911)
Other income (expense), net (219) 181 1,940 404
Total other income (loss), net (15,359) (14,713) (28,543) (12,441)
Income (loss) before income taxes (11,612) (19,871) (13,908) 804,814
Income tax benefit (expense) 4,911 4,620 5,162 (168,147)
Net income (loss) $ (6,701) $ (15,251) $ (8,746) $ 636,667
Earnings Per Share, Basic and Diluted:        
Basic net income (loss) per share (USD per share) $ (0.42) $ (0.81) $ (0.54) $ 32.51
Shares used in basic per share calculations (shares) 16,082,000 18,770,000 16,222,000 19,586,000
Diluted net income (loss) per share (USD per share) $ (0.42) $ (0.81) $ (0.54) $ 31.29
Shares used in diluted per share calculations (shares) 16,082,000 18,770,000 16,222,000 20,349,000
Royalties        
Revenues:        
Total revenues $ 9,005 $ 9,767 $ 22,751 $ 35,931
Captisol        
Revenues:        
Total revenues 23,389 6,849 68,966 24,357
Contract revenue        
Revenues:        
Total revenues $ 9,454 $ 8,192 $ 24,712 $ 32,991